Ciclo de Seminários: Biomarcadores Urinários no Diagnóstico e Seguimento do CANCRO da BEXIGA.
A utilização de novos biomacadores urinários no cancro da bexiga tem potencial aplicação clínica no diagnóstico, vigilância de recorrência e mesmo na seleção de doentes elegíveis para terapias dirigidas, venha conhecer a experiência dos centros de referência que já adotaram a sua utilização.
Os seminários irão ser realizados em modo presencial.*
* Se pretender aceder à transmissão em vídeo deverá, também, inscrever-se para o efeito.Um evento
em parceria com
Programa:
Seminário 24/10/22 18:30h
Tema: Illumination of a Vision—Urinary Based Biomarkers for Bladder Cancer on the Way to Clinical Decisions—Dream or Nightmare?
Keynote speaker: Prof Doutor Thorsten H. Hecke
Moderador: Prof. Doutor Ricardo Leão
Local: Coimbra, Auditório da CUF Coimbra
PROF. DOUTOR THORSTEN H ECKE
Thorsten Hecke works at the Department of Urology of the HELIOS Hospital, in Bad Saarow, Germany.
He has undertaken several studies evaluating the utility of combined Bladder Cancer Biomarkers in the frameworks of surveillance, molecular prognostication, tumor subtyping, therapy decision; ultimately aiming at illumination of a Vision of Urinary Based Biomarkers on the Way to Clinical Decisions, and whether this will become a Dream or a Nightmare?
Eventos já realizados:
Seminário 22/07/22 16:30h
Tema: Prospective validation of FGFR screening by urine-based testing within the BRIDGister real-world clinicopathological register trial.
Keynote speaker: Prof. Doutor Ralph M. Wirtz
Moderador: Prof. Doutor Ricardo Leão
Local: Porto, Centro de Investigação Médica –FMUP
PROF. DOUTOR Ralph M. Wirtz
Ralph Wirtz is one of the founding members of STRATIFYER Molecular Pathology GmbH, at Cologne, Germany.
He develops close collaboration with clinical research organizations to perform stratified trials. Recently he co-authored a prospective validation study of urine based FGFR screening by Uromonitor within the real-world clinicopathological register trial BRIDGister.
The objective of the study was to prospectively evaluate FGFR mutation detetion in matched urine and tissue samples from patients suspicious of bladder cancer and undergoing first TURB within the framework of the BRIDGister RealWorld Experience trial.
Seminário 29/07/22 8:30h
Tema: Diagnosis and follow-up of NMIBC including (urinary) biomarkers.
Keynote speaker: Prof Doutor J. Alfred Witjes
Moderador: Prof. Doutor Carlos Martins-Silva
Local: Porto, Centro de Investigação Médica -FMUP
PROF. DOUTOR J. A. WITJES
Fred Witjes is professor in oncological urology. His research interest is translational and clinical research in bladder, prostate and testicular cancer.
He has many training and teaching activities. He is a member of several international societies, and he chairs, amongst others, the Dutch guidelines committee on bladder cancer and the EAU guidelines committee on metastatic and muscle- invasive bladder cancer. He is reviewer for many, and editor of several urological and oncological journals. He is involved in and leads many studies and projects which has resulted in many lectures and over 600 (peer reviewed) publications, reviews and book chapters.
His H index in Dec 2021 was 90.
Seminário 08/09/22 19:00h
Tema: Preliminary results of the SOLUSION study: Urine-based Detection of NMIBC Interventional Trial
Keynote speaker: Prof Doutor Nessn H. Azawi
Moderador: Prof. Doutor Luís Figueiredo
Local: Braga, Auditório do Trofa Saúde - Hospital Braga Sul
PROF. DOUTOR NESSN H. AZAWI
Nessn Azawi is Chief Urologyst and Head of the Research unit (Urology) at the Zealand University Hospital: Roskilde in Denmark.
He is the Principal investigator of the SOLUSION trial, which aims at evaluating the potential clinical impact of a highly sensitive urinary marker, Uromonitor, regarding possible reduction in number of cystoscopies. The hypothesis is that the use of a sensitive urinary marker regarding recurrent tumor will enable to reduce the number of follow-up cystoscopies without risk of delaying diagnosis of recurrence and progression cystoscopies compared to flexible cystoscopy alone.